Ownership and insider activity for Mereo BioPharma Group plc (MREO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment.
Price
| Price | $0.27 |
| Market Cap | $42M |
| Exchange | NASDAQ |
| Country | GB |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53.6M | $50.0M | $25.0M | $20.9M | $31.3M | $126.7M | $68.2M | $57.4M | $69.8M | $41.0M |
| Short-term Investments | 0 | $2.5M | $2.5M | $720634 | $748034 | $769470 | 0 | 0 | 0 | 0 |
| Receivables | $995784 | $509350 | 0 | 0 | 0 | 0 | $3.2M | $3.7M | $3.2M | $2.0M |
| Inventory | -$53.9M | -$2.5M | -$293328 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $60.8M | $63.2M | $34.5M | $40.3M | $40.7M | $134.3M | $75.2M | $63.8M | $74.8M | $45.0M |
| Property, Plant & Equipment | $173869 | $153361 | $148935 | $15.3M | $2.2M | $3.4M | $2.2M | $1.6M | $984000 | $381000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $25.8M | $33.0M | $32.6M | $58.9M | $43.3M | $33.2M | $29.0M | $1.1M | $643000 | $516000 |
| Total Assets | $86.8M | $96.3M | $67.3M | $114.5M | $86.1M | $171.0M | $77.4M | $66.5M | $76.4M | $45.9M |
| Accounts Payable | $1.2M | $2.6M | $5.6M | $8.1M | $4.3M | $3.1M | $3.5M | $2.3M | $2.4M | $1.3M |
| Short-term Debt | 0 | $1.9M | $6.8M | $20.1M | 0 | 0 | $13.3M | 0 | $5.5M | 0 |
| Total Current Liabilities | $3.2M | $9.6M | $16.2M | $39.6M | $11.7M | $17.0M | $24.4M | $9.5M | $13.8M | $4.3M |
| Long-term Debt | $3.1M | $18.8M | $14.6M | $7.1M | $22.1M | $19.5M | 0 | $4.4M | 0 | 0 |
| Total Liabilities | $7.5M | $33.9M | $34.5M | $61.2M | $106.6M | $51.9M | $26.0M | $16.0M | $15.4M | $5.0M |
| Retained Earnings | -$33.6M | -$79.3M | -$111.2M | -$193.5M | -$423.5M | -$401.6M | -$404.6M | -$419.6M | -$462.9M | -$501.0M |
| Total Equity | $79.3M | $62.5M | $32.8M | $53.3M | -$20.5M | $119.0M | $51.4M | $50.5M | $61.0M | $40.9M |
| Total Debt | $3.1M | $20.8M | $21.5M | $42.9M | $24.5M | $22.7M | $15.4M | $6.0M | $6.4M | $202000 |
| Net Debt | -$50.5M | -$31.8M | -$6.1M | $21.3M | -$7.6M | -$104.9M | -$52.8M | -$51.5M | -$63.4M | -$40.8M |
| Working Capital | $57.6M | $53.6M | $18.3M | $737856 | $28.9M | $117.4M | $50.8M | $54.3M | $60.9M | $40.7M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 5.88 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -8.98 |
Profitability
| Return on Equity | -74.76% |
| Return on Invested Capital | -111.41% |
| Return on Assets | -80.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACIU · ALDX · CADL · CAPR · CTNM · IMMP · KYTX
Explore sector: Healthcare · Biotechnology
More sections of MREO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks